Hisamitsu Overactive Bladder Transdermal Drug To Enter Phase III Trial
This article was originally published in PharmAsia News
Executive SummaryJapan's largest transdermal drug maker Hisamitsu plans to start a domestic Phase III trial for HOB-294 (transdermal oxybutynin) for overactive bladder. A Phase II trial has shown improvement in symptoms such as urination urgency and pollakiuria. Hisamitsu aims to start the subsequent trial next year. Oxybutynin is developed by French drug giant Sanofi-Aventis. (Click here for more - Japanese language
You may also be interested in...
An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.
San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.